• 1. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 2. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990
• 3. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 4. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 5. Fe/S-Catalyzed synthesis of 2-benzoylbenzoxazoles and 2-quinolylbenzoxazoles via redox condensation of o-nitrophenols with acetophenones and methylquinolines?
  Thi Thu Tram Nguyen,Thanh Binh Nguyen Org. Biomol. Chem., 2021,19, 6015-6020

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Disaccharides
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Carbohydrates and carbohydrate conjugates Disaccharides

Comprehensive Overview of Heparin Disaccharide I-H Trisodium Salt (CAS No. 136098-04-9): Structure, Applications, and Research Insights

Heparin disaccharide I-H trisodium salt (CAS No. 136098-04-9) is a chemically defined oligosaccharide derivative of heparin, a naturally occurring glycosaminoglycan (GAG). This compound is widely utilized in biochemical and pharmaceutical research due to its role in studying heparin-protein interactions, carbohydrate chemistry, and glycobiology. Its trisodium salt form enhances solubility, making it ideal for in vitro assays and drug discovery applications.

The molecular structure of heparin disaccharide I-H consists of two sugar units linked by α(1→4) glycosidic bonds, with sulfation patterns critical for biological activity. Researchers focus on its ability to mimic heparin-binding domains, which are pivotal in modulating cell signaling pathways and anticoagulant mechanisms. Recent studies highlight its potential in anti-inflammatory therapies and cancer metastasis inhibition, aligning with growing interest in glycan-based therapeutics.

In the context of biomedical research trends, CAS No. 136098-04-9 is frequently searched alongside terms like "heparin-derived oligosaccharides", "GAG mimetics", and "structure-activity relationship of heparin". These keywords reflect user interest in its structure-function analysis and therapeutic potential. Notably, the compound’s role in COVID-19 research has surged, as heparin derivatives are investigated for their ability to inhibit viral entry mechanisms via spike protein interactions.

From a technical perspective, heparin disaccharide I-H trisodium salt is characterized by high-performance liquid chromatography (HPLC) and nuclear magnetic resonance (NMR) to ensure purity and structural integrity. Its applications extend to enzyme substrate studies, particularly for heparanase and sulfatases, enzymes implicated in extracellular matrix remodeling and disease progression. This aligns with the demand for precision tools in glycomics research.

The compound’s relevance in drug development is underscored by its use in high-throughput screening (HTS) platforms to identify novel heparin-binding inhibitors. Additionally, its low immunogenicity and biocompatibility make it a candidate for biomaterial coatings, such as in medical implants and tissue engineering scaffolds. These applications resonate with the rising focus on personalized medicine and regenerative therapies.

For researchers sourcing CAS No. 136098-04-9, common queries include "synthesis protocol for heparin disaccharides", "buy heparin disaccharide I-H trisodium salt", and "heparin disaccharide solubility and stability". Addressing these, suppliers often provide technical datasheets detailing storage conditions (-20°C, desiccated) and handling guidelines to prevent degradation. The compound’s molecular weight (~700 Da) and charge density are also critical for experimental design.

Emerging discussions in scientific forums and publications explore the compound’s utility in nanotechnology, such as glyconanoparticle synthesis for targeted drug delivery. Its anionic properties facilitate interactions with cationic carriers, a hotspot in nanomedicine research. Furthermore, its eco-friendly extraction methods from marine sources cater to the sustainability trends in biochemical production.

In summary, heparin disaccharide I-H trisodium salt (CAS No. 136098-04-9) bridges fundamental research and translational applications, driven by its multifunctional glycosaminoglycan properties. As glycoscience advances, this compound remains a cornerstone for unraveling heparin’s biological roles and innovating next-generation biotherapeutics.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)